AstraZeneca's Calquence Gains FDA Approval for First-Line Treatment of MCL

Recently, AstraZeneca announced that its BTK inhibitor, Calquence (acalbrutinib), has received FDA approval for a new indication. It is now authorized for use in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not suitable for autologous stem cell transplantation. This approval marks Calquence as the first BTK inhibitor approved for first-line therapy in MCL.

Approval Based on Positive Clinical Results

The FDA's decision was primarily based on positive outcomes from a Phase III clinical trial assessing Calquence in combination with standard treatment (SOC: bendamustine + rituximab). The study evaluated the efficacy and safety of this regimen in MCL patients aged 65 years or older who had not received prior treatment. The trial's main endpoint was progression-free survival (PFS).

Results indicated that patients receiving Calquence experienced a statistically and clinically significant improvement in PFS compared to the SOC group, with median PFS durations of 66.4 months versus 49.6 months (HR=0.73, P=0.0160). Additionally, there was a positive trend toward improved overall survival (OS) in the Calquence group (HR=0.86, P=0.27).

Overview of MCL and BTK Inhibitors

MCL is a rare form of B-cell non-Hodgkin lymphoma characterized by both indolent and aggressive clinical-pathological features. Over the past decade, several new therapies have been developed for MCL, particularly Bruton’s tyrosine kinase inhibitors (BTKis), which have demonstrated significant efficacy in treating these patients. Currently, five BTK inhibitors are available globally for MCL treatment: the first-generation ibrutinib and the second-generation agents acalbrutinib, zanubrutinib, obuibrutinib, and the non-covalent BTK inhibitor pirtobrutinib.

Calquence has gained a competitive edge as it becomes the first approved BTK inhibitor for first-line treatment in MCL. Its main competitor, BeiGene's zanubrutinib, is still in Phase III trials for first-line MCL treatment.

Ibrutinib has shown a median PFS benefit of nearly 28 months, which is significantly higher than the 17 months observed for acalbrutinib in the ECHO trial. However, despite its success in PFS, ibrutinib has not translated this benefit into improved overall survival, preventing its approval for first-line therapy.

AstraZeneca's Calquence approval represents a significant advancement in the treatment landscape for MCL, offering a new option for patients who cannot undergo stem cell transplantation. With its proven efficacy in a clinical setting, Calquence is poised to play a crucial role in the management of this challenging disease, further establishing its position in the evolving field of oncology.